新たなゲノム解析によると、アルツハイマー病は皮膚、肺、腸などの臓器での炎症から始まる可能性があり、脳の症状が現れる数十年も前から起こり得る。研究者らは数十万人の遺伝子データを解析し、リスク遺伝子が脳外でより活発に働いていることを発見した。この視点は予防・治療戦略を根本的に変える可能性がある。
アルツハイマー病は伝統的に脳に起源を持つものとされてきたが、詳細なゲノム研究がこの見方を覆している。デンマークのNovo Nordisk Foundation Center for Basic Metabolic Researchに所属するセザール・クーニャ氏とそのチームは、欧州アルツハイマー・認知症バイオバンクから採取したアルツハイマー病患者8万5千人以上と非患者48万5千人の遺伝子データを解析した。また、40の身体部位と100の脳領域にわたる500万の単一細胞における遺伝子活性も評価した。
AIによるレポート AIによって生成された画像 事実確認済み
Researchers at Boston Children’s Hospital report that mutations commonly associated with clonal blood-cell expansion and some blood cancers were enriched in microglia-like immune cells in Alzheimer’s brains and were also detectable in matched blood samples. The Cell study proposes that age- or injury-related weakening of the blood-brain barrier could allow mutated blood immune cells to enter the brain, potentially amplifying inflammation and contributing to neurodegeneration.
A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.
AIによるレポート
A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.
Researchers from the Institute for Bioengineering of Catalonia and collaborating institutions report that engineered “supramolecular” nanoparticles restored aspects of blood-brain barrier function in Alzheimer’s-model mice, rapidly lowering brain amyloid-β and producing improvements on behavioral and memory tests.